Issue link: https://www.e-digitaleditions.com/i/1518209
Inhalation APRIL 2024 7 PQRI and membership, contact the PQRI Secretariat at PQRISec retariat@pqri.org. Development, Global Bioequiv- alence Harmonisation (GBHI 2024), and Challenges and Oppor- tunities for Modi ed Release Oral Drug Product Development. For more information Please follow us on LinkedIn and visit the PQRI website to stay informed about PQRI's ongoing activities and upcoming events. Past PQRI webinar recordings are available here: https://pqri. org/events/. For questions about e Development Technical Com- mittee (DTC) is actively engaged in several ongoing projects and collaborations. A new working group will launch in 2024 on Creation of Recommended Best Practices for Extractable Analy- sis to Reduce Uncertainty Due to Variation in Practice. e DTC is exploring collaborative opportuni- ties with the Center for Research on Complex Generics (CRCG) as well as the SEMI Nano-Bio Mate- rials (NBMC) consortium. Other areas of future exploration include materials disruption and impact of sustainability initiatives, disrup- tive and transformative technol- ogies, and materials quali cation and control for drug/device com- bination products focusing on design controls, regulatory aspects and safety. PQRI workshops PQRI conducted several high- impact workshops and events in 2023. PQRI collaborated with the FDA to jointly organize an FDA/PQRI virtual workshop on the "Regulatory Framework for the Utilization of Arti cial Intel- ligence in Pharmaceutical Man- ufacturing: An Opportunity for Stakeholder Engagement." e workshop attracted a large audi- ence and the free- owing dialogue was most bene cial as industry communicated to the FDA the increasing implementation of AI technology in their companies (see FDA FRAME website for more details). A hybrid PQRI workshop cov- ering the Global Regulatory and Technical Challenges of Titanium Dioxide (TiO2) Use in Pharmaceuticals was held in 2023. e discussions were highly informative, and learnings were incorporated into a position paper that was shared with reg- ulatory agencies earlier in 2024. e position paper is posted on the PQRI website. Other workshops in 2024 will cover the following topics: MIDD Approaches in Ediatric Formulation ■ Non-PFAS chemistry. ■ Coating integrity results comparable to FEP and PTFE. ■ Environmentally acceptable solvents. ■ Pharmaceutical performance comparable to fluoropolymer- coated cans. ■ A lower carbon footprint than other coatings. Metered dose inhaler can coating experts for nearly 30 years. Our new proprietary MDI coating has: Learn more at biomerics.com/MDICoating